One-pager reviewing what we’ve learned from previous efficacy trials, the product pipeline and where we are today and future directions toward finding a vaccine that works.
AIDS Vaccine Science for Busy Advocates – Current AIDS Vaccine R&D Pipeline
AIDS Vaccine Science for Busy Advocates – RV144: Building on a breakthrough
A one-page document describing RV144, the first AIDS vaccine trial to show protection against HIV in humans, and plans to further this research.
AIDS Vaccine Science for Busy Advocates – Passive Immunization: An important piece of the puzzle
A one-page document describing passive immunization, the transfer of pre-made antibodies, and its potential for HIV prevention.
HIV Vaccines: Key messages
This is a three-page document providing main points surrounding vaccine research. For a shorter one-page version of this, click here.
2005 AVAC Report: AIDS Vaccines at the Crossroads
This year’s Report offers recommendations for the field in general, the Global HIV Vaccine Enterprise, policy makers, researchers and communities. Some of these recommendations will be familiar because AVAC has made them before, and they are reiterated because it is AVAC’s belief that they are still needed. The Report also provides an update on tenofovir pre-exposure prophylaxis research.
2004 AVAC Report: AIDS Vaccine Trials: Getting the Global House in Order
This year’s Report focuses on how the field is readying itself for the road ahead. Several chapters address different aspects of “readiness”—a term that means different things to different people, but that is at the heart of the AIDS vaccine advocacy agenda today.
From Research to Reality: Investing in HIV Prevention Research in a Challenging Landscape
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2013 report finds that the US government was again the biggest contributor and calls for other countries and sectors to step up to end a seven-year trend of flat funding. It also profiles growing interest in research on a therapeutic vaccines.
Investing to End the AIDS Epidemic: A New Era for HIV Prevention Research & Development
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2012 report finds increased investment by private foundations was unable to make up for the effects of the economic downturn. It also highlights the contributions to prevention research of trial participants.
Capitalizing on Scientific Progress: Investment in HIV Prevention R&D in 2010
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2011 report describes the funding environment in the wake of a number of the findings of efficacy in the RV144, CAPRISA, iPrEx and HPTN 025 trials and calls for sustained funding to build on these results.
2013 AVAC Report: Research and Reality
Research & Reality calls on funders and researchers to capitalize on lessons learned from a range of recent HIV prevention trials via better problem solving, more critical thinking and coordinated action. This year’s AVAC Report identifies progress and gaps in large-scale human trials, rollout of proven options and ongoing research for new advances that women and men will want to use.